Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer.

Sci Rep · 2024 · PMC11189402 · PMID 38890392

Europe PMC DOI

hedged sentences

0.0650

closest p · 1.3× alpha

0.0750

boldest claim

The sentences

did not reach statistical significanceP = 0.065so close (0.05 < p ≤ 0.1)

Interestingly, patients with moderate differentiation, ≤ 2 metastatic sites, and a baseline plasma meanVAF < 2.29% exhibited a trend towards improved PFS, although these observations did not reach statistical significance (Hazard Ratio [HR] 0.24, 95% Confidence Interval [CI] 0.05–1.09, P = 0.065; HR 0.22, 95% CI 0.05–1.02, P = 0.052; HR 0.36, 95% CI 0.13–1.02, P = 0.055, respectively) (The cutoff values for maxVAF < 2.54% and meanVAF < 2.29% were based on median values).

also in 75,278 other papers

showed a trendP = 0.069so close (0.05 < p ≤ 0.1)

However, it is noteworthy that the presence of detectable ctDNA post-treatment showed a trend towards worse OS (HR 7.13, 95% CI 0.86–59.3, P = 0.069).

also in 33,225 other papers

near-significantP = 0.075so close (0.05 < p ≤ 0.1)

Importantly, baseline plasma meanVAF < 2.29% showed near-significant potential in predicting PFS (HR 0.08, 95% CI 0.01–1.28, P = 0.075), potentially serving as an independent predictor of PFS (Tables S3 and S4 ).

also in 1,650 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.